Back to top

FDA expands marketing of 23andMe to include medication metabolism

November 6, 2018
No votes yet
Technology

Summary/Abstract

The FDA expanded the marketing of the 23andMe Personal Genome Service Pharmacogenetic Reports test to provide information about 33 genetic variants that may be linked with a patient’s ability to metabolize some medications to help inform discussions with a health care provider, according to an agency press release.